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Targeting mineralocorticoid (-like)
interventions to treat
hyperkalemia in chronic
hemodialysis patients
To the Editor: After some initial success, Farese et al.1
propose further studies on the use of glycyrrhetinic acid
food supplementation to reduce hyperkalemia in chronic
hemodialysis patients, presumably by activating mineralocor-
ticoid-stimulated colonic potassium excretion. Patients with
hyperkalemia in predialysis chronic renal failure either
have or do not have evidence of hypoaldosteronism (relative
to their plasma potassium).2–4 Prior stratiﬁcation of hyperka-
lemic patients in future studies into those with hypoaldoster-
onism, or not, should help to more clearly deﬁne the
risk–beneﬁt of mineralocorticoid (-like) interventions.
The issue is how best to deﬁne those hyperkalemic patients
with hypoaldosteronism, because of the stimulatory effect of
potassium on aldosterone secretion. An algorithm for this has
been developed, which substantially differentiates patients with
hyperkalemia (45.3mmol/l) due to hypoaldosteronism from
those with renal aldosterone resistance (predominantly due to
pseudohypoaldosteronism).4 The algorithm, FAldo¼ plasma
aldosterone/(plasma K4.2), provides a set point for FAldo at
280pmol/l or 10ng/dl: results below the limit suggest
hypoaldosteronism, while those above the limit indicate the
contrary.4 Stratiﬁcation, by this algorithm, of hyperkalemic
hemodialysis patients might contribute to the information
gained from future studies on mineralocorticoid (-like) supple-
mentation, including the utility of the algorithm in this situation.
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The Authors Reply: The correct assessment of hypo- and
hyperaldosteronism in dialysis patients represents a non-
trivial issue inﬂuenced by different measurement methods
and different sampling times, and is furthermore complicated
by the lack of validated normal values for this population.
Both hypo- and hyperaldosteronism have been described in
dialysis patients1,2 and are potentially inﬂuenced by several
factors, such as serum potassium concentration, hyper- or
hypovolemia, antihypertensive medications, and target-organ
resistance in patients with renal failure.
As over-activation of the mineralocorticoid receptor (MR)
has been associated with adverse cardiovascular effects, we
fully agree with the comment of Dr Adam3 that stratiﬁcation
of patients into those with hypoaldosteronism and those with
hyperaldosteronism may help to identify individuals with the
most favorable risk–beneﬁt relationship when MR-activating
xenobiotics like glycyrrhetinic acid are prescribed. The
algorithm proposed by Dr Adam4 may represent a simple
and valuable method to identify patients with renal failure
and hypoaldosteronism in whom a maximal effect on the
reduction of serum potassium concentration can be expected
when glycyrrhetinic acid or other MR-stimulating agents
are used.
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Vasopressin and
microalbuminuria: is it vasopressin
per se or is it salt intake?
To the Editor: In his commentary,1 Dr Cirillo focuses on the
Prevention of Renal and Vascular Endstage Disease (study)
data showing that copeptin plasma levels are associated with
albuminuria.2 He emphasizes that vasopressin needs to be
paid more attention while analyzing kidney dysfunction. He
also raises two questions, which we would like to answer.
First, he points out that the inverse association between
vasopressin and glomerular ﬁltration rate (GFR) that we
found2 seems to be in contradiction to the increase in GFR
that Bankir and colleagues reported after vasopressin admin-
istration in short-term intervention studies.3 A possible
explanation could well be that exposure to vasopressin in the
short term induces glomerular hyperﬁltration, and that this
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